Third Wave on Track for HPV MDx Filing This Year; Q1 Revenues Drop 15 Percent | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Amid an ongoing patent dispute with Digene, Third Wave Technologies officials said last week that the firm is on track to submit its human papillomavirus diagnostic to the US Food and Drug Administration this year and expects to receive US clearance of its cystic fibrosis test in the third quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.